UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 138

Sortiert nach

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

British journal of cancer, 2016-04, Vol.114 (8), p.863-871

2016

Volltextzugriff (PDF)

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

The New England journal of medicine, 2019-12, Vol.381 (25), p.2416-2428

2019

Volltextzugriff (PDF)

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

The lancet oncology, 2020-05, Vol.21 (5), p.699-709

2020

Volltextzugriff (PDF)

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

European journal of cancer (1990), 2017-09, Vol.82, p.237-246

2017

Volltextzugriff (PDF)

Influence of the injection technique on the false negative rate of SLNE in multifocal breast cancer

Nuclear medicine, 2008-01, Vol.47 (5), p.216

2008

Volltextzugriff (PDF)

Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancer

The New England journal of medicine, 2000-02, Vol.342 (8), p.525-533

2000

Volltextzugriff (PDF)

Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients

Bone marrow transplantation (Basingstoke), 1997-06, Vol.19 (12), p.1223-1228

1997

Volltextzugriff (PDF)

Abstract P1-12-03: Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized Adebar trial

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-12-03

2016

Volltextzugriff (PDF)

Abstract P5-15-04: CTX and CTX-related direct medication costs saved by testing biomarkers uPA and PAI-1 in primary breast cancer: Results of a prospective multi-center study at Certified Breast Centers in Germany

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-15-04

2012

Volltextzugriff (PDF)

Abstract P5-14-06: Analysis of test-therapy concordance for biomarkers uPA and PAI-1 in primary breast cancer in clinical hospital routine: Results of a prospective multi-center study at Certified Breast Cancers in Germany

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-14-06

2012

Volltextzugriff (PDF)

The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy - A comparative analysis from the prospective multi-center randomized ADEBAR trial

Clinical breast cancer, 2016

2016

Volltextzugriff (PDF)

Therapie der peripartale Cardyomyopathie bei einer 32-jährigen Erstgravida mit Bromocriptin

Geburtshilfe und Frauenheilkunde, 2012-07, Vol.72 (7)

2012

Volltextzugriff (PDF)

PD07-01: Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel vs. FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: Final Survival Analysis of the German ADEBAR Phase III Study

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.PD07-01-PD07-01

2011

Volltextzugriff (PDF)

Abstract S2-2: Multivariate Analysis of Obesity and Disease Free Survival in Patients with Nodal Positive Primary Breast Cancer — The ADEBAR Trial

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.S2-S2-2

2010

Volltextzugriff (PDF)

Obesity and disease-free survival in patients with nodal-positive early-stage breast cancer: The ADEBAR trial

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.541-541

2010

Volltextzugriff (PDF)

Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC 120 in the adjuvant treatment of breast cancer patients: The German ADEBAR study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.535-535

2010

Volltextzugriff (PDF)

Oxygenation of mammary tumors as evaluated by ultrasound-guided computerized-pO2-histography

Advances in experimental medicine and biology, 1994, Vol.345, p.451

1994

Volltextzugriff (PDF)

Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel Is Equieffective, but Less Toxic Than FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: The German ADEBAR Phase III Study

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.604-604

2009

Volltextzugriff (PDF)

Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: The ADEBAR trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1020-1020

2011

Volltextzugriff (PDF)

A multicentric observational trial with metastatic breast cancer (MBC) patients on pegylated liposomal doxorubicin (PLD) regimen

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1139-1139

2008

Volltextzugriff (PDF)

Pelvic minus fetal diameter: value of pelvimetry in the detection of cephalopelvic disproportion

European radiology, 1995-08, Vol.5 (4)

1995

Volltextzugriff (PDF)

The excretion of ketorolac tromethamine into breast milk after multiple oral dosing

European journal of clinical pharmacology, 1989-01, Vol.36 (5), p.521-524

1989

Volltextzugriff (PDF)

MBU einfacher, schneller und billiger?

Geburtshilfe und Frauenheilkunde, 2012, Vol.72 (7)

2012

Volltextzugriff (PDF)

Die postpartale Kardiomyopathie (PPCM) – Der Weg zur Diagnose anhand einer Kasuistik

Geburtshilfe und Frauenheilkunde, 2012, Vol.72 (7)

2012

Volltextzugriff (PDF)

Therapie der peripartale Cardyomyopathie bei einer 32-jährigen Erstgravida mit Bromocriptin

Geburtshilfe und Frauenheilkunde, 2012

2012

Volltextzugriff (PDF)

1 – 25 von 138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(110)

Publikationsform

Sprache

Deutsch
(94)
Englisch
(45)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Female
(63)
Humans
(58)
Pregnancy
(32)
Adult
(31)
Life Sciences & Biomedicine
(23)
Middle Aged
(23)
Science & Technology
(23)
Aged
(19)
Infant, Newborn
(17)
Oncology
(15)
Breast Cancer
(13)
Aged, 80 And Over
(12)
Breast Neoplasms - Drug Therapy
(10)
Risk Factors
(9)
Chemotherapy
(8)
Prospective Studies
(8)
Quality Of Life
(8)
Animals
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Breast Neoplasms - Pathology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Influence of the injection technique on the false negative rate of SLNE in multifocal breast cancer

Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancer

Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients

Abstract P1-12-03: Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized Adebar trial

Abstract P5-15-04: CTX and CTX-related direct medication costs saved by testing biomarkers uPA and PAI-1 in primary breast cancer: Results of a prospective multi-center study at Certified Breast Centers in Germany

Abstract P5-14-06: Analysis of test-therapy concordance for biomarkers uPA and PAI-1 in primary breast cancer in clinical hospital routine: Results of a prospective multi-center study at Certified Breast Cancers in Germany

The impact of age on quality of life in breast cancer patients receiving adjuvant chemotherapy - A comparative analysis from the prospective multi-center randomized ADEBAR trial

Therapie der peripartale Cardyomyopathie bei einer 32-jährigen Erstgravida mit Bromocriptin

PD07-01: Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel vs. FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: Final Survival Analysis of the German ADEBAR Phase III Study

Abstract S2-2: Multivariate Analysis of Obesity and Disease Free Survival in Patients with Nodal Positive Primary Breast Cancer — The ADEBAR Trial

Obesity and disease-free survival in patients with nodal-positive early-stage breast cancer: The ADEBAR trial

Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC 120 in the adjuvant treatment of breast cancer patients: The German ADEBAR study

Oxygenation of mammary tumors as evaluated by ultrasound-guided computerized-pO2-histography

Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel Is Equieffective, but Less Toxic Than FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: The German ADEBAR Phase III Study

Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: The ADEBAR trial

A multicentric observational trial with metastatic breast cancer (MBC) patients on pegylated liposomal doxorubicin (PLD) regimen

Pelvic minus fetal diameter: value of pelvimetry in the detection of cephalopelvic disproportion

The excretion of ketorolac tromethamine into breast milk after multiple oral dosing

MBU einfacher, schneller und billiger?

Die postpartale Kardiomyopathie (PPCM) – Der Weg zur Diagnose anhand einer Kasuistik

Therapie der peripartale Cardyomyopathie bei einer 32-jährigen Erstgravida mit Bromocriptin

Suchergebnisse filtern